Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 3 of the last 4 fiscal years.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 48 % of short-term debt in 2025; threshold 65 %.
-
Busy address KBO
17 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
272BIO from Gent, company number BE0762638249, closed financial year 2025 with a result of € -631,558 after tax. For that financial year 272BIO recorded a gross margin of € 104,252 and equity of € -225,308. Compared with financial year 2024, the result moved from € -457,209 to € -631,558. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on January 12, 2026.
€ -225,308
▼ € 631,558 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -631,558
▼ 38 % more loss than in 2024
Profit after tax over the fiscal year.
€ 350,764
▼ 69% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -1.4 million.
People and assets in 2025
5.2
▲ 1.7 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 590,340
▲ 45% vs 2024
€ 113,500 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 9,055
▲ 24% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 155,788
▼ 22% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 81,399
▲ 71% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -18,400 | € 44,511 | € 17,671 | € 104,252 | ▲ € 86,581 |
| Profit after taxes | € -70,217 | € -278,324 | € -457,209 | € -631,558 | ▼ € 174,349 |
| Equity | € -58,217 | € -336,541 | € 406,250 | € -225,308 | ▼ € 631,558 |
| Total debts | € 79,192 | € 906,191 | € 1,174,819 | € 934,909 | ▼ 20% |
| Cash | € 13,708 | € 45,056 | € 1,132,392 | € 350,764 | ▼ 69% |
| Retained profit | € -70,217 | € -348,541 | € -805,750 | € -1,437,308 | ▼ € 631,558 |
| Bank debt | € 0 | € 629,136 | € 0 | € 0 | |
| Balance sheet total | € 20,975 | € 569,650 | € 1,581,070 | € 709,601 | ▼ 55% |
| Employees (FTE) | - | 2.8 | 3.5 | 5.2 | ▲ 1.7 |
Key figures of 272BIO, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 January 2027.
What happened to 272BIO?
What happened at 272BIO in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 631,558. Source: NBB ↗
- Tom Hayward became a director. NBB
- Christine Labeur became a director. NBB
- Liz Littlewood became a director. NBB
- New establishment in Gent. KBO
- Start of the company according to the CBE. KBO
- Charles Edward Owen became a director. NBB
In short
From € 70,217 loss in 2022 to € 631,558 loss in 2025.
Paid € 2,657 in corporate taxes since 2022.
On average € 20,000 of value added per employee in 2025.
Management
Behind 272BIO are Charles Edward Owen, Tom Hayward, Christine Labeur and Liz Littlewood. The same people are also behind Xpert Protein.
Directors
According to the 2025 annual accounts
since 2021
since 2024
since 2024
since 2024
Establishments
Establishment units
Physical locations of this company
Suzanne Tassierstraat 1
9052 Gent
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 17 companies are registered at this address.
All companies at this address →VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY
€ 52.6 million revenue · 2025
ORIONIS BIOSCIENCES
€ 11.6 million revenue · 2025
LO²CUS Gent
€ 1.7 million gross margin · 2024
S-Biomedic
€ 4.4 million gross margin · 2025
VIB BIO-INCUBATOR
€ 536,162 gross margin · 2025
+12 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Barracuda
Hosting
GOOGLE - Google LLC, US
Domain
Domain
272bio.com
Registered
2019-10-19
Registrar
Mesh Digital Limited
Expires
2027-10-19
Website info
Features
Security
Details
- Company number
- 0762.638.249
- VAT number
- BE 0762.638.249
- Registered office
- Suzanne Tassierstraat 1, 9052 Gent
- Names & denominations
- 272BIO
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 28 January 2021
- Peppol
- Active · Active since 13 Apr 2026
- Contact
- 272bio.com [email protected]
- Activities · NACE
Vervaardiging van geneesmiddelen